<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602053</url>
  </required_header>
  <id_info>
    <org_study_id>CVIA 066</org_study_id>
    <nct_id>NCT03602053</nct_id>
  </id_info>
  <brief_title>Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia</brief_title>
  <acronym>ROTAVAC</acronym>
  <official_title>An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bharat Biotech International Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Infectious Disease Research in Zambia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate and compare the immunogenicity of ROTAVAC® and
      ROTAVAC 5D 28 days after the last dose of the vaccine, when administered to infants in a
      three-dose schedule at 6, 10 and 14 weeks of age.

      The study will also assess the reactogenicity of the vaccine 7 days after each vaccination
      and safety from first vaccination up to 4 weeks after the last vaccination with ROTAVAC® and
      ROTAVAC 5D, and of Rotarix® when administered to infants in a two-dose schedule at 6 and 10
      weeks of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a Phase IIb, single center, randomized, controlled, open label
      study with 3 groups of infants (n=150 per group) receiving either three doses of ROTAVAC®
      three doses of ROTAVAC 5D or two doses of Rotarix®. 450 participants will be randomized
      (1:1:1) to receive ROTAVAC®, ROTAVAC 5D or Rotarix®. The three doses of ROTAVAC® and ROTAVAC
      5D will be administered at 6, 10 and 14 weeks of age whereas two doses of Rotarix® will be
      administered at 6 and 10 weeks of age. All vaccines will be administered concomitantly with
      EPI vaccines including Diphtheria, Tetanus, Pertussis, Haemophilus influenzae type b and
      Hepatitis B vaccine (DTwP-Hib-HepB), Pneumococcal conjugate vaccine and OPV at 6, 10 and 14
      weeks and IPV at week 14 (when switched to in Zambia). The participants will be monitored for
      30 minutes following vaccine administration for immediate adverse events.

      A blood sample will be obtained from all the participating infants before first vaccination
      and four weeks after the last vaccine dose. This would mean that the blood sample will be
      collected at approximately 14 weeks of age for infants in the Rotarix® arm and 18 weeks for
      infants in the ROTAVAC® groups.

      Enhanced passive/Active surveillance for vaccine reactogenicity (solicited reactions) over
      the 7-day period after each vaccination will be conducted on all infants. In addition,
      surveillance for unsolicited AEs, SAEs including intussusception will be carried out over the
      period between first vaccination and four weeks after the last vaccination on all infants.

      The study will compare the immunogenicity of the two formulations of ROTAVAC® i.e. ROTAVAC®
      vs. ROTAVAC 5D and will descriptively analyze the immune response to Rotarix®. Primary
      immunogenicity analysis of all samples will be based on a validated ELISA which uses strain
      WC3 as a substrate. A subset of the samples (50 pairs/arms) collected will also be tested by
      a validated ELISA which uses strain 89-12 (G1P8 virus) as a substrate. This trial will
      generate immunogenicity and safety data on ROTAVAC® and ROTAVAC 5D outside of India.
      Presentation of data to Zambian Ministry of Health, WHO and in peer reviewed open access
      publications will be key audiences targeted for communication of results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase IIb, single center, randomized, controlled, open label study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentration using WC3 as the viral lysate</measure>
    <time_frame>28 day after last dose of the study vaccine</time_frame>
    <description>GMC of serum anti-rotavirus IgA antibodies as measured by enzyme linked immunosorbent assay (ELISA) using WC3 as the viral lysate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate Adverse Events</measure>
    <time_frame>within 30 minutes' post-vaccination.</time_frame>
    <description>Percentage of participants reporting immediate adverse events after each vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Adverse Events</measure>
    <time_frame>7 day period after each vaccination.</time_frame>
    <description>Percentage of participants reporting solicited post-vaccination reactogenicity (fever, diarrhea, vomiting, decreased appetite, irritability, decreased activity level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events</measure>
    <time_frame>from first vaccination through 4 weeks after the last vaccination.</time_frame>
    <description>Percentage of participants reporting unsolicited AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Adverse Events</measure>
    <time_frame>from first vaccination through 4 weeks after the last vaccination of each study participant. Immunogenicity</time_frame>
    <description>Percentage of participants reporting SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate in each of the three vaccine arms as measured by ELISA using WC3 as the viral lysate</measure>
    <time_frame>28 days after last dose of study vaccine.</time_frame>
    <description>Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if a baseline concentration is &lt; 20 U/mL or a post-vaccination serum anti-rotavirus IgA antibody concentration of ≥ 2-fold baseline level if a baseline concentration is ≥ 20 U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rate in each of the three vaccine arms as measured by ELISA using WC3 as the viral lysate</measure>
    <time_frame>at baseline and 28 days after last dose of study vaccine</time_frame>
    <description>Seropositivity is defined as serum anti-rotavirus IgA antibody concentration ≥ 20 U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse rate in each of the three vaccine arms as measured by ELISA using WC3 as the viral lysate</measure>
    <time_frame>28 days after last dose of study vaccine</time_frame>
    <description>Seroresponse will be assessed as a four-fold, three-fold and two- fold rise in antibody concentration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in each of the three vaccine arms as measured by ELISA using WC3 as the viral lysate</measure>
    <time_frame>at 28 days after last dose of study vaccine in reference to baseline.</time_frame>
    <description>GMFR in each of the three vaccine arms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Geometric mean concentrations using strain 89-12 as the viral lysate</measure>
    <time_frame>28 days after the last dose of a study vaccine.</time_frame>
    <description>GMCs of serum anti-rotavirus IgA antibodies in each of the three vaccine arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion using strain 89-12 as the viral lysate</measure>
    <time_frame>28 days after the last dose of a study vaccine.</time_frame>
    <description>Seroconversion rate in each of the three vaccine arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Seropositivity using strain 89-12 as the viral lysate</measure>
    <time_frame>at baseline and 28 days after last dose of study vaccine</time_frame>
    <description>Seropositivity rate in each of the three vaccine arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) using strain 89-12 as the viral lysate</measure>
    <time_frame>at 28 days after last dose of study vaccine in reference to baseline.</time_frame>
    <description>GMFR in each of the three vaccine arms.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Diarrhea</condition>
  <condition>Diarrhea Rotavirus</condition>
  <arm_group>
    <arm_group_label>ROTAVAC 5D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROTAVAC®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotarix®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ROTAVAC®</intervention_name>
    <description>0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.</description>
    <arm_group_label>ROTAVAC®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ROTAVAC 5D</intervention_name>
    <description>0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.</description>
    <arm_group_label>ROTAVAC 5D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix®</intervention_name>
    <description>1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.</description>
    <arm_group_label>Rotarix®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy infant as established by medical history and clinical examination before
             entering the study.

          2. Age: 6-8 weeks (42-56 days, both days inclusive) confirmed by Immunization Record.

          3. Infants received age-appropriate EPI vaccines till enrolment.

          4. Ability and willingness to provide informed consent as per local consenting
             procedures.

          5. Parent can be contacted on phone and confirms intention to remain in the study area
             with the participant during the study period.

        Exclusion Criteria:

          1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrolment
             (temporary exclusion).

          2. Presence of fever on the day of enrolment (temporary exclusion).

          3. Acute disease at the time of enrolment (temporary exclusion).

          4. Concurrent participation in another clinical trial throughout the entire timeframe of
             this study.

          5. Presence of severe malnutrition (weight-for-height z-score &lt; -3SD median).

          6. Any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal,
             hematological, endocrine, immunological, dermatological, neurological, cancer or
             autoimmune disease) as determined by medical history and/or physical examination which
             would compromise the child's health or is likely to result in non-conformance to the
             protocol.

          7. History of congenital abdominal disorders, intussusception, abdominal surgery

          8. Known or suspected impairment of immunological function based on medical history and
             physical examination.

          9. Prior receipt or intent to receive rotavirus and other age specified EPI vaccines
             outside of the study center and during study participation.

         10. A known sensitivity or allergy to any component of the study vaccine.

         11. Clinically detectable significant congenital or genetic defect.

         12. History of persistent diarrhea (defined as diarrhea more than 14 days).

         13. Participant's parents not able, available or willing to accept active follow-up by the
             study staff.

         14. Has received any immunoglobulin therapy and/or blood products since birth or planned
             administration during the study period.

         15. History of chronic administration (defined as more than 14 days) of immunosuppressants
             including corticosteroids. Infants on inhaled or topical steroids may be permitted to
             participate in the study.

         16. History of any neurologic disorders or seizures.

         17. Any medical condition in the parents/infants that, in the judgment of the
             investigator, would interfere with or serves as a contraindication to protocol
             adherence or a participant's parent's/legally acceptable representative's ability to
             give informed consent.

         18. Participant is a direct descendant (child or grandchild) of any person employed by the
             Sponsor, the CRO, the PI or study site personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niraj Rathi, MD</last_name>
    <role>Study Director</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Research Centre</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX-PI-PIL.PDF</url>
    <description>Rotarix (Product Information).</description>
  </link>
  <link>
    <url>https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_ppi.pdf</url>
    <description>Rotateq (Product Information).</description>
  </link>
  <link>
    <url>https://www.path.org/media-center/path-welcomes-new-promising-study-results-for-rotavirus-vaccine-candidate/</url>
    <description>PATH welcomes new promising study results for rotavirus vaccine candidate.</description>
  </link>
  <link>
    <url>http://www.pharmabiz.com/NewsDetails.aspx?aid=108851&amp;sid=2</url>
    <description>Bharat Biotech receives National Technology Award for Rotavac from President of India</description>
  </link>
  <reference>
    <citation>Tate JE, Burton AH, Boschi-Pinto C, Parashar UD; World Health Organization–Coordinated Global Rotavirus Surveillance Network. Global, Regional, and National Estimates of Rotavirus Mortality in Children &lt;5 Years of Age, 2000-2013. Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105. doi: 10.1093/cid/civ1013.</citation>
    <PMID>27059362</PMID>
  </reference>
  <reference>
    <citation>Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine. 2012 Apr 27;30 Suppl 1:A7-14. doi: 10.1016/j.vaccine.2011.12.096.</citation>
    <PMID>22520139</PMID>
  </reference>
  <reference>
    <citation>Beres LK, Tate JE, Njobvu L, Chibwe B, Rudd C, Guffey MB, Stringer JS, Parashar UD, Chilengi R. A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia. Clin Infect Dis. 2016 May 1;62 Suppl 2:S175-82. doi: 10.1093/cid/civ1206.</citation>
    <PMID>27059353</PMID>
  </reference>
  <reference>
    <citation>Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012 Jun 9;379(9832):2151-61. doi: 10.1016/S0140-6736(12)60560-1. Epub 2012 May 11. Erratum in: Lancet. 2012 Oct 13;380(9850):1308.</citation>
    <PMID>22579125</PMID>
  </reference>
  <reference>
    <citation>Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, Velasquez DE, Bosomprah S, Jiang B. Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants. PLoS One. 2016 Mar 14;11(3):e0150100. doi: 10.1371/journal.pone.0150100. eCollection 2016.</citation>
    <PMID>26974432</PMID>
  </reference>
  <reference>
    <citation>Tate JE, Yen C, Steiner CA, Cortese MM, Parashar UD. Intussusception Rates Before and After the Introduction of Rotavirus Vaccine. Pediatrics. 2016 Sep;138(3). pii: e20161082. doi: 10.1542/peds.2016-1082. Epub 2016 Aug 24.</citation>
    <PMID>27558938</PMID>
  </reference>
  <reference>
    <citation>Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010 Jan 28;362(4):289-98. doi: 10.1056/NEJMoa0904797.</citation>
    <PMID>20107214</PMID>
  </reference>
  <reference>
    <citation>Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):606-14. doi: 10.1016/S0140-6736(10)60889-6. Epub 2010 Aug 6.</citation>
    <PMID>20692030</PMID>
  </reference>
  <reference>
    <citation>Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):615-23. doi: 10.1016/S0140-6736(10)60755-6. Epub 2010 Aug 6.</citation>
    <PMID>20692031</PMID>
  </reference>
  <reference>
    <citation>Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliyil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK; India Rotavirus Vaccine Group. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014 Jun 21;383(9935):2136-43. doi: 10.1016/S0140-6736(13)62630-6. Epub 2014 Mar 12.</citation>
    <PMID>24629994</PMID>
  </reference>
  <reference>
    <citation>Isanaka S, Guindo O, Langendorf C, Matar Seck A, Plikaytis BD, Sayinzoga-Makombe N, McNeal MM, Meyer N, Adehossi E, Djibo A, Jochum B, Grais RF. Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger. N Engl J Med. 2017 Mar 23;376(12):1121-1130. doi: 10.1056/NEJMoa1609462.</citation>
    <PMID>28328346</PMID>
  </reference>
  <reference>
    <citation>Mpabalwani EM, Simwaka CJ, Mwenda JM, Mubanga CP, Monze M, Matapo B, Parashar UD, Tate JE. Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged &lt;5 Years in Lusaka, Zambia. Clin Infect Dis. 2016 May 1;62 Suppl 2:S183-7. doi: 10.1093/cid/civ1027.</citation>
    <PMID>27059354</PMID>
  </reference>
  <reference>
    <citation>Bishop R. Discovery of rotavirus: Implications for child health. J Gastroenterol Hepatol. 2009 Oct;24 Suppl 3:S81-5. doi: 10.1111/j.1440-1746.2009.06076.x. Review.</citation>
    <PMID>19799704</PMID>
  </reference>
  <reference>
    <citation>Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005 Jan-Feb;15(1):29-56. Review.</citation>
    <PMID>15484186</PMID>
  </reference>
  <reference>
    <citation>Kang G, Arora R, Chitambar SD, Deshpande J, Gupte MD, Kulkarni M, Naik TN, Mukherji D, Venkatasubramaniam S, Gentsch JR, Glass RI, Parashar UD; Indian Rotavirus Strain Surveillance Network. Multicenter, hospital-based surveillance of rotavirus disease and strains among indian children aged &lt;5 years. J Infect Dis. 2009 Nov 1;200 Suppl 1:S147-53. doi: 10.1086/605031.</citation>
    <PMID>19817593</PMID>
  </reference>
  <reference>
    <citation>Rodrigo C, Salman N, Tatochenko V, Mészner Z, Giaquinto C. Recommendations for rotavirus vaccination: A worldwide perspective. Vaccine. 2010 Jul 12;28(31):5100-8. doi: 10.1016/j.vaccine.2010.04.108. Epub 2010 May 14. Review.</citation>
    <PMID>20472032</PMID>
  </reference>
  <reference>
    <citation>Simpson E, Wittet S, Bonilla J, Gamazina K, Cooley L, Winkler JL. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health. 2007 Oct 5;7:281.</citation>
    <PMID>17919334</PMID>
  </reference>
  <reference>
    <citation>Levy K, Hubbard AE, Eisenberg JN. Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis. Int J Epidemiol. 2009 Dec;38(6):1487-96. doi: 10.1093/ije/dyn260. Epub 2008 Dec 4. Review.</citation>
    <PMID>19056806</PMID>
  </reference>
  <reference>
    <citation>Atchison CJ, Tam CC, Hajat S, van Pelt W, Cowden JM, Lopman BA. Temperature-dependent transmission of rotavirus in Great Britain and The Netherlands. Proc Biol Sci. 2010 Mar 22;277(1683):933-42. doi: 10.1098/rspb.2009.1755. Epub 2009 Nov 25.</citation>
    <PMID>19939844</PMID>
  </reference>
  <reference>
    <citation>Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006 Jan 5;354(1):11-22.</citation>
    <PMID>16394298</PMID>
  </reference>
  <reference>
    <citation>Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliyil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK; India Rotavirus Vaccine Group. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. 2014 Aug 11;32 Suppl 1:A110-6. doi: 10.1016/j.vaccine.2014.04.079.</citation>
    <PMID>25091663</PMID>
  </reference>
  <reference>
    <citation>Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis. 1994 Apr;169(4):900-4.</citation>
    <PMID>8133107</PMID>
  </reference>
  <reference>
    <citation>Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis. 1993 Aug;168(2):282-7.</citation>
    <PMID>8393054</PMID>
  </reference>
  <reference>
    <citation>Aiyar J, Bhan MK, Bhandari N, Kumar R, Raj P, Sazawal S. Rotavirus-specific antibody response in saliva of infants with rotavirus diarrhea. J Infect Dis. 1990 Dec;162(6):1383-4.</citation>
    <PMID>2172405</PMID>
  </reference>
  <reference>
    <citation>Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014 Feb 3;32(6):651-6. doi: 10.1016/j.vaccine.2013.12.017. Epub 2013 Dec 25.</citation>
    <PMID>24374502</PMID>
  </reference>
  <reference>
    <citation>Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med. 1983 Jul 14;309(2):72-6.</citation>
    <PMID>6304516</PMID>
  </reference>
  <reference>
    <citation>Glass RI, Bhan MK, Ray P, Bahl R, Parashar UD, Greenberg H, Rao CD, Bhandari N, Maldonado Y, Ward RL, Bernstein DI, Gentsch JR. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis. 2005 Sep 1;192 Suppl 1:S30-5. Review.</citation>
    <PMID>16088802</PMID>
  </reference>
  <reference>
    <citation>Ing DJ, Glass RI, Woods PA, Simonetti M, Pallansch MA, Wilcox WD, Davidson BL, Sievert AJ. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child. 1991 Aug;145(8):892-7.</citation>
    <PMID>1650128</PMID>
  </reference>
  <reference>
    <citation>Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan kM, Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J. 2003 Oct;22(10):914-20.</citation>
    <PMID>14551493</PMID>
  </reference>
  <reference>
    <citation>Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, Vanprapar N, Simasathien S, Phavichitr N, Bock HL, Damaso S, Hutagalung Y, Han HH. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Hum Vaccin. 2010 Mar 26;6(3). pii: 10428. Epub 2010 Mar 26.</citation>
    <PMID>20220306</PMID>
  </reference>
  <reference>
    <citation>Estes MK, Graham DY, Smith EM, Gerba CP. Rotavirus stability and inactivation. J Gen Virol. 1979 May;43(2):403-9.</citation>
    <PMID>39115</PMID>
  </reference>
  <reference>
    <citation>Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J Gen Virol. 1985 Dec;66 ( Pt 12):2725-30.</citation>
    <PMID>2999315</PMID>
  </reference>
  <reference>
    <citation>Feng N, Burns JW, Bracy L, Greenberg HB. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol. 1994 Dec;68(12):7766-73. Erratum in: J Virol 1995 May;69(5):3246.</citation>
    <PMID>7966566</PMID>
  </reference>
  <reference>
    <citation>Graham DY, Dufour GR, Estes MK. Minimal infective dose of rotavirus. Arch Virol. 1987;92(3-4):261-71.</citation>
    <PMID>3028333</PMID>
  </reference>
  <reference>
    <citation>Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M, Bean JA, Sack DA, Bernstein DI. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. J Infect Dis. 2006 Dec 15;194(12):1729-36. Epub 2006 Nov 6.</citation>
    <PMID>17109346</PMID>
  </reference>
  <reference>
    <citation>Mandomando I, Weldegebriel G, de Deus N, Mwenda JM. Feasibility of using regional sentinel surveillance to monitor the rotavirus vaccine impact, effectiveness and intussusception incidence in the African Region. Vaccine. 2017 Mar 23;35(13):1663-1667. doi: 10.1016/j.vaccine.2017.01.072. Epub 2017 Mar 1.</citation>
    <PMID>28242070</PMID>
  </reference>
  <reference>
    <citation>Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, Saksena M, Rao CD, Gentsch JR, Parashar U, Maldonado Y, Ward RL, Bhan MK. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine. 2006 Jul 26;24(31-32):5817-23. Epub 2006 May 12.</citation>
    <PMID>16735085</PMID>
  </reference>
  <reference>
    <citation>Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S, Vrati S; Rotavirus Vaccine Development Group. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2009 Aug 1;200(3):421-9. doi: 10.1086/600104.</citation>
    <PMID>19545211</PMID>
  </reference>
  <reference>
    <citation>Chandola TR, Taneja S, Goyal N, Antony K, Bhatia K, More D, Bhandari N, Cho I, Mohan K, Prasad S, Harshavardhan G, Rao TS, Vrati S, Bhan MK. ROTAVAC(®) does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017 May 16;3(5):e00302. doi: 10.1016/j.heliyon.2017.e00302. eCollection 2017 May.</citation>
    <PMID>28560356</PMID>
  </reference>
  <reference>
    <citation>Ella R, Bobba R, Muralidhar S, Babji S, Vadrevu KM, Bhan MK. A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India. Hum Vaccin Immunother. 2018 Jul 3;14(7):1791-1799. doi: 10.1080/21645515.2018.1450709. Epub 2018 Apr 12.</citation>
    <PMID>29543547</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Infectious Disease Research in Zambia</investigator_affiliation>
    <investigator_full_name>Roma Chilengi</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <keyword>Rotavirus</keyword>
  <keyword>ROTAVAC</keyword>
  <keyword>Rotavirus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

